Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.
about
Hepatitis B virus infection and risk of coronary artery disease: a meta-analysisFatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis CHCV screening in a cohort of HIV infected and uninfected homeless and marginally housed women in San Francisco, CaliforniaHealth utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trialsEffectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.The impact of hepatitis C virus outside the liver: Evidence from Asia.Impact of hepatitis C virus therapy on metabolism and public health.Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD.In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.Impact of hepatitis C oral therapy in portal hypertension.Comment on Nuño Solinís R, et al. "Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence".Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease.Chronic hepatitis C liver microenvironment: role of the Th17/Treg interplay related to fibrogenesis.Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin.Historical epidemiology of hepatitis C virus in select countries-volume 4.Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France.Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.Association between pre-sarcopenia, sarcopenia, and bone mineral density in patients with chronic hepatitis C.Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature.Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?Bleeding from a Small-Intestinal Ulcer Associated with Chronic Hepatitis C.Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations.Cardiovascular Involvement in Chronic Hepatitis C Virus Infections – Insight from Novel Antiviral Therapies.A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D.Orbital Pseudotumor as an Extrahepatic Complication of Chronic HCV Infection.The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost AnalysisImprovement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund DataClinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund DataAchieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in AustraliaA comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyEconomic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus
P2860
Q28068804-5C4F6D66-076F-4864-B8FE-2CD4CEB4848FQ28079826-9922C652-92B7-45E5-B940-EBBFAE2E446CQ30235178-9E819F3B-865E-4E2D-BFAB-BB8F89EB7D1EQ30837913-F37A030B-471F-4A0A-9FA6-33CEA9213F70Q37615658-D3F67C4E-65FE-48DD-B22C-D8C62009CDFDQ38806948-C6C776E3-EF8E-4035-AFCC-F0DD82731B07Q38982462-5AFB0C35-ADB5-40B2-BC43-9F3C8A541047Q39040729-FCC07FF1-1FE6-4E94-8545-CF0A1CFA049AQ40057348-6FC77FA6-3DB5-4861-969A-7C0072CF629EQ40118666-5E258EC4-E733-488D-91C1-1E2300462AB4Q40121053-8047A8A2-B17D-4CB2-9149-C401A1EC20D2Q40135838-35CDE1DD-FE7A-4964-BF20-CCAA1C519C0FQ40215825-423C2F8C-E444-4F89-888A-B4A7FFC8FDCFQ42334110-F07732E7-DC1D-4E1F-A9D0-953A6568EC9FQ42345870-627CE37D-D2D2-4CBA-A332-B342CCA142FDQ42370354-190C5B7F-6110-4CAE-825A-C8A65AB077F9Q42378927-8CF7B491-44FA-4E2F-A42A-97D35013FEB7Q45324202-453C6A93-789F-4886-8FF9-D86F1C2BBE8AQ45325255-E2B7EF9F-2CEC-43C2-8026-0A5DA5BBF174Q45326148-C5854DC6-F1AD-4EF0-92DF-37B50094756EQ47549008-E8214E20-5D74-40BD-A327-B3B61BAC888AQ47551529-8C066507-8AA7-48A7-9F72-EEA46F14AD11Q47555610-9555EDE3-5F8B-42B3-91C7-083204BB29BDQ47595176-E363FC06-8919-4E7F-885A-E01C268FB731Q51366504-FE549F41-EA0D-4DA9-B16F-27E5AA6B3C09Q54216578-46A4A2AC-98CF-44D0-ABBC-9D4BA86F789EQ54263016-F60929A7-27D2-46E6-B1D6-D96A86BFA12EQ55027429-4945E4CD-40C1-45C2-9BBC-02E74B2EC8CAQ55284802-776926CD-A666-4265-BF86-BFE3944A7776Q55406543-0226F2AF-FF74-44E6-B65B-EE3C3966DEF4Q55553786-59A87439-8653-4312-B054-F23A02A1C9A8Q56654940-4E00101F-0A04-4355-9DA0-1AF5560AA9D6Q56890376-D173335B-6DEA-4C36-9F07-6286543D83CFQ56890393-2BFD7D4E-3D93-4288-86DC-265EFC3933CCQ57135444-3896520D-6CDB-4819-A5F9-0520433E91BBQ57173478-A0C8152C-AA86-45E5-B599-D544D27A5210Q57301030-54ED05D9-7C00-4633-B00D-7A8972C37E04
P2860
Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Extrahepatic Manifestations of ...... of Life, and Economic Burden.
@en
type
label
Extrahepatic Manifestations of ...... of Life, and Economic Burden.
@en
prefLabel
Extrahepatic Manifestations of ...... of Life, and Economic Burden.
@en
P2093
P1433
P1476
Extrahepatic Manifestations of ...... of Life, and Economic Burden.
@en
P2093
Ayoade Adeyemi
Haesuk Park
Linda Henry
Maria Stepanova
Zobair Younossi
P304
P356
10.1053/J.GASTRO.2016.02.039
P407
P577
2016-02-25T00:00:00Z